Neurosigma

Develops and commercializes trigeminal nerve stimulation (TNS) devices for treatment of psychiatric disorders

placeLos Angeles, California, United States calendar_todayFounded 2008 groups8 employees language neurosigma.com

Registered entities

Investor mix

4 investors on record.

Investor typeCountShare
Private equity125%
Other / undisclosed375%
Coming soon